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point on the graph of the meta-regression 
where the lower 95 % prediction band inter-
sects with the horizontal (no-eff ect) axis. 
An STE using negatively controlled trials 
has been demonstrated for low-density 
lipoprotein cholesterol and statin therapy 12 
and, more recently, for diastolic and systolic 
blood pressure and antihypertensive ther-
apy (KJ and M Lassere, unpublished data). 
 In summary, in comparison with stroke 
prevention, there is a shortage of trials 
demonstrating that treatment-associated 
diff erences in achieved levels of albuminu-
ria or estimated glomerular fi ltration rate 
translate into reductions in important 
outcomes. Without these, one cannot sub-
stantiate an argument for the use of albu-
minuria or estimated glomerular fi ltration 
rate as a surrogate in treatment decisions. 
Stevens  et al. , 13 in a recent review, suggest 
that a by-trial analysis of studies measur-
ing both proteinuria and renal outcomes 
is feasible with published data. Until such 
analyses are available, there will remain 
uncertainty surrounding treatment or 
policy recommendations based on these 
risk factors. 
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 PPAR-  transcriptional activity is 
required to combat doxorubicin-
induced podocyte injury in mice 
 Kiyoshi  Mori 1 ,  Masashi  Mukoyama 1 and  Kazuwa  Nakao 1 
 Immunosuppressants and inhibitors of the renin angiotensin system 
are major reagents to treat nephrotic syndrome, but their clinical 
effects are not necessarily satisfactory. Injection of doxorubicin in 
several strains of mice causes nephrotic syndrome – like disorder. 
Zhou  et al. report that PPAR-  expression is downregulated in 
murine doxorubicin nephropathy and a PPAR-  agonist, fenofibrate, 
partially ameliorates the disorder induced likely through stabilization 
of nephrin expression and suppression of apoptosis in podocytes, 
providing a new preventive strategy. 
 Kidney International (2011)  79, 1274 – 1276;  doi: 10.1038/ki.2011.36 
 Podocyte injury plays an important role in 
various proteinuric disorders. Because 
podocytes in adult humans and rodents 
have little proliferative activity, cellular 
stress in podocytes tends to accumulate, 
and podocyte loss cannot be recovered. 1 
Th erefore, protection of podocytes in renal 
disorders should be a major strategy to pre-
vent worsening of renal failure, especially 
in chronic disease, but drugs clinically avail-
able for that goal are not very eff ective. 
 Peroxisome proliferator-activated 
receptors (PPARs) possess various activi-
ties, including not only enhancement of 
fatty acid oxidization but also suppression 
of infl ammation, apoptosis, and fi brosis. 2 
Fenofi brate is a PPAR-  agonist widely 
used to treat hypertriglyceridemia 
patients, and its use may also be benefi cial 
for cardiovascular disorders. Animal 
studies have shown that treatment with 
PPAR-  ligand or transgenic overexpres-
sion of PPAR-  in proximal tubules can 
ameliorate the development of cisplatin-
induced or renal ischemia / reperfusion-
induced acute kidney injury and diabetic 
nephropathy. 3,4 
 Doxorubicin (adriamycin, or DOX) is 
an anthracycline class of chemotherapy 
reagent used to treat solid or  hematopoietic 
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malignancies. DOX causes glomeruloscle-
rosis and tubulointerstitial injury in 
several selected strains of mice. 5 Docosa-
hexaenoic acid (a PPAR agonist) amelio-
rates DOX-induced apoptosis of renal 
tubular cells. 6 Zhou  et al. 7 (this issue) 
investigated whether fenofi brate inhibits 
podocyte injury and proteinuria in DOX-
induced nephropathy among two murine 
strains. Th e BALB / c strain of mouse is 
highly susceptible to nephrotoxic eff ects 
of DOX, whereas C57BL / 6 mice are resist-
ant. 5 In PPAR-  knockout (KO) mice on 
a 129 / SvJ background, which has usually 
been used in earlier studies to generate 
KO mice, intravenous challenge of DOX 
caused more severe renal damage among 
KO mice than among wild-type mice. 7 
Renal disorder on a 129 / SvJ background 
was slightly milder than, but basically 
similar to, that on a BALB / c background. 
Furthermore, fenofibrate partially 
suppressed the development of DOX 
nephro pathy in both strains. PPAR-  KO 
mice grew up with almost normal kid-
neys, whereas DOX treatment reduced 
glome rular PPAR-  mRNA expression. 
Th ese fi ndings suggest that a certain level 
of PPAR-  activity is required to maintain 
normal glomerular structure under 
stressed conditions. Importantly, 
inhibition of DOX nephropathy by fenof-
ibrate was not observed in PPAR-  KO 
mice; this excludes a possibility of off -tar-
get eff ects by fenofi brate. Th e  in vivo and 
 in vitro findings are summarized in 
 Figure 1 (ref.  7 ). 
 Cardiotoxicity is a major side eff ect of 
DOX in humans, whereas proteinuria or 
acute renal failure is not so common. 
Th ese observations suggest the presence 
of modifi er genes that aff ect the sensitivity 
of organs and animals to DOX. Continual 
eff ort to identify genes that confer suscep-
tibility in mice has recently led to the 
conclusion that mutation in protein kinase, 
DNA-activated, catalytic poly peptide 
( Prkdc ) gene and subsequent depletion of 
mitochondrial DNA in the kidney aft er 
DOX treatment are the mechanism of 
DOX nephropathy in mice. 5  Prkdc plays an 
important role in DNA repair and mainte-
nance of mitochondrial DNA inte grity, 
especially in non-replicating cells such as 
podocytes and cardiocytes. 
 Diabetic nephropathy, which is usually 
accompanied by massive proteinuria, is 
almost pandemic, acting as the leading 
cause of end-stage renal failure. Antipro-
teinuric actions of fenofi brate have been 
reported in rodents and humans, but the 
evidence is, unfortunately, not very 
strong. Fenofi brate treatment of type 2 
diabetic mice resulted in dramatic 
suppression of nephropathy, but the 
eff ects appear to be mediated largely by 
 normalization of hyperglycemia. 8 Aft er 
streptozotocin treatment to cause diabe-
tes, PPAR-  KO mice exhibited more pro-
nounced renal histological changes than 
wild-type mice at 4 months, but albu-
minuria in KOs was not greater than that 
in controls until 2 months. 9 Furthermore, 
PPAR-  protein expression was elevated 
threefold in diabetic mice compared with 
controls, 9 as opposed to reduced expres-
sion in DOX nephropathy. 7 In a large-
scale human trial, treatment of type 2 
diabetes patients with fenofi brate reduced 
albuminuria progression, 10 but renopro-
tective eff ects of fenofi brate have not been 
convincingly reproduced in following tri-
als. Glomerular fi ltration rate may be sup-
pressed by fenofi brate through inhibition 
of vasodilatory prostaglandin synthesis, 3 
but an adequate correction of glomerular 
hyperfi ltration might be renoprotective 
in the long term, as we have learned 
from blockade of the renin – angiotensin 
system. 
 A lot of future study has to be done to 
determine whether mitochondrial DNA 
damage in podocytes is a frequent cause, 
or simply a result, of proteinuric disor-
ders, and whether its correction leads to 
preservation of renal function in human 
disorders. Furthermore, renoprotective 
effects of fenofibrate should be tested 
in large-scale,  long-term human 
trials whose primary end points are 
progression of protein uria and renal 
dysfunction. 
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 Figure 1  |  Proposed mechanism of doxorubicin-induced nephropathy in disease-susceptible 
mouse strains. Treatment with fenofibrate attenuates the injury, whereas PPAR-  knockout 
mice show more severe renal phenotypes than wild-type mice do. 7 Not all combinations were 
examined by Zhou  et al. 7 
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